Balancing Between Concentration and Volume when Developing Patient-Centric Biologics
Update: 2025-08-12
Description
Summary:
When developing patient-centric products for biologics, different doses, expressed by different combinations of volume/concentration may require different delivery devices. As a result, it takes a great deal of time and effort in planning and coordinating the formulation and device activities. In this podcast, Pharma and Drug Delivery executives from Nanoform, Pfizer, GSK, Takeda and Kymanox discuss how they facilitate partnerships between drug product development, device engineering and clinical study teams to determine how to balance concentration and volume and develop optimal devices for delivery and commercialization. Specifically:
When developing patient-centric products for biologics, different doses, expressed by different combinations of volume/concentration may require different delivery devices. As a result, it takes a great deal of time and effort in planning and coordinating the formulation and device activities. In this podcast, Pharma and Drug Delivery executives from Nanoform, Pfizer, GSK, Takeda and Kymanox discuss how they facilitate partnerships between drug product development, device engineering and clinical study teams to determine how to balance concentration and volume and develop optimal devices for delivery and commercialization. Specifically:
- Impact on increasing concentration of drugs on deliverability
- Technical feasibility of manufacturing larger volume devices
- Patient tolerability and human factors that impact patient adherence
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
